Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplet Therapy with Bempedoic Acid, Ezetimibe, and Atorvastatin in Hypercholesterolemia
NCT03051100Phase 2Completed
- Sponsor
- Esperion Therapeutics
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of bempedoic acid in hypercholesterolemia (2 arms), sponsored by Esperion Therapeutics. Primary endpoint: Percent Change From Baseline in Low-density Lipoprotein Cholesterol at 6 weeks. Started Jan 2017; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03051100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051100.